Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

GSK to widen COVID-19 antibody treatment trial after safety clearance

Tue, 6th Oct 2020 13:00

Oct 6 (Reuters) - GlaxoSmithKline and partner Vir
Biotechnology will expand their trial of an experimental
antibody to treat COVID-19 after initial use by a group of
volunteers did not raise any safety concerns.

The two partners in August started testing the antibody on
early-stage COVID-19 patients, hoping to keep symptoms from
progressing.

Various firms are running tests in this promising class of
antiviral drugs to combat the pandemic.

After testing the drug on 20 U.S. participants for safety,
the trial will now expand as planned to 1,300 patients globally.

Half the participants will be randomly assigned to a control
group receiving a placebo.

Interim trial results may be available as early as the end
of 2020. Complete efficacy results are expected as early as
January or later in the first quarter of 2021.

(Reporting by Ludwig Burger; editing by Jason Neely)

Related Shares

More News

Tuesday broker round-up

(Sharecast News) - BP: Barclays upgrades to top pick with a target price of 475p.

Today 14:00

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

Today 11:52

TOP NEWS: GlaxoSmithKline and Medicago hail Covid-19 vaccine results

TOP NEWS: GlaxoSmithKline and Medicago hail Covid-19 vaccine results

Today 09:06

LONDON BRIEFING: Vodafone shares slide 6% after annual revenue decline

LONDON BRIEFING: Vodafone shares slide 6% after annual revenue decline

Today 08:21

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.